

## Supplementary materials

### Contents:

**Table S1:** Primers used for construction and verification of *cdr4* deletion strain.

**Table S2:** Gene specific primers used for qRT-PCR.

**Table S3:** Transcript levels of genes encoding oligopeptide (OPT) transporters and peptide transporters (PTR/POT).

**Table S4:** Summary of SNPs and Indel mutations in the tested strains.

**Table S5:** The information of SNPs.

**Table S6:** The information of the Indels.

**Figure S1:** *N. crassa* acquired multidrug resistance under azole stress.

**Figure S2:** Drug susceptibility test of gene knockout mutants for transmembrane transporters.

**Figure S3:** Effects of *cdr4* deletion or overexpression on drug susceptibility.

**Figure S4:** Drug susceptibility test of knockout mutants of genes with SNPs or Indels in the evolved resistant strains.

**Figure S5:** Transcript levels of catalase encoding genes in the evolved resistant strains and WT.

**Table S1.** Primers used for construction and verification of *cdr4* deletion strains.

Primer name	Sequence(5'→3')	Note
<i>cdr4</i> <sup>KO</sup> -5F	GTAACGCCAGGGTTTTCCAGTCACGACGGGTAACGAG- TATATCCGTGG	
<i>cdr4</i> <sup>KO</sup> -5R	ATCCACTTAACGTTACTGAAATCTCCAACGACGAGTACAG- TGACGAAGG	
<i>cdr4</i> <sup>KO</sup> -3F	CTCCTTCAATATCATCTTCTGTCTCCGACGAAGAGAGAGAA- TAGCGAGG	For construction of <i>cdr4</i> deletion strain
<i>cdr4</i> <sup>KO</sup> -3R	GCGGATAACAATTTACACAGGAAACAGCAGAGACCACAAC- GTAAGTGC	
<i>cdr4</i> <sup>KO</sup> -HphF	GTCGGAGACAGAAGATGATATTGAAGGAGC	
<i>cdr4</i> <sup>KO</sup> -HphR	GTTGGAGATTTACAGTAACGTTAAGTGGAT	
<i>cdr4</i> <sup>KO</sup> -Vef F1	CGAAGTCGATACCCATTTC	
<i>cdr4</i> <sup>KO</sup> -Vef R1	CTTGTATGGAGCAGCAGACGC	For transformant verification by PCR
<i>cdr4</i> <sup>KO</sup> -Vef F2	TTGTGATCCGCTGGACGACT	
<i>cdr4</i> <sup>KO</sup> -Vef R2	ACCACCGAACATCCGAAACGA	

**Table S2.** Gene specific primers used for qRT-PCR.

Gene	Locus No.	Forward primer(5'→3')	Reverse primer(5'→3')	Source
<i>β-tubulin</i>	NCU04540	CCCAA- GAACATGATGGCTGCTTCT	TTGTTCTGAACGTTGCG- CATCTGG	(1)
<i>erg11</i>	NCU02624	AAATCGATTACGGCTAC- GGTCTCG	TATCGCTACCATCCAC- GTTCTGA	
<i>cdr4</i>	NCU05591	GCTTTGGAAATGGATGGTGAC- GCT	AAATGCAGAGGGCGGTCTTA- GAGT	
<i>erg1</i>	NCU08280	CGTGGTGCTGGCGAGACATTA	CCTCCTTCCAAATCGTCGGCA	
<i>chs-1</i>	NCU03611	GTCGACCTACATCAACATCC	GTGGCTTCTCAATCTCTTCC	
<i>chs-3</i>	NCU04251	CACGGTTGTACATGGGTATG	GAGACGATGAGGGTGTAGAA	
<i>chs-4</i>	NCU09324	CCACACACTCTCGTTTCTC	GCTTGACCGACTCTCATTT	
<i>abc-8</i>	NCU07546	TTCTATCGCTTCTGGATGATTG	GCCAGTGAGTCCTTGTAATG	
<i>abc-3</i>	NCU09975	TCGTCTTTGGCGCTTAC	TAGCCAGTGACGAGATAGTT	
<i>atr1-2</i>	NCU10009	GGAGTACATGGAAC- CTTTCTTC	CAAATCCCTCCACCTGTTATC	
<i>msf-9</i>	NCU05079	TCCTCTTCCTTCCCATCTAC	GTAGGAACAAGAAGGACGATAG	This study
NCU03171	NCU03171	GCTGTGCACTCTCGTTATATTC	GAGGTCCAAAGATCTCTCCT	
<i>msf-8</i>	NCU08738	TTCGCCATTGGTGGTATTT	GATCGGTAACAACCGAAGAG	
NCU10763	NCU10763	ACAGTTCCTCAGCTCCTT	CATAGGCGAGCCAACATATC	
<i>opt-4</i>	NCU06352	CCAGCACAGCAGCATTTA	CATGTAGTGGCCTAGTTTGAG	
NCU08397	NCU08397	GAGGTTACTCTGAACGTCTTG	CGGGATCTTGACATAATGGG	
<i>opt-3</i>	NCU07894	GTGGTTGAGCTGGATCTATG	CCACTCCACACTCACTCTA	
NCU17261	NCU17261	TTCAACTGGATGACATGGA- TAG	GAAGAAAGGCTGGGATAGTG	
<i>opt-5</i>	NCU17269	CGGTGGTGTTTATGGGATAC	ATGGTCACATTAGGCAAGTC	
<i>opt-1</i>	NCU09773	GCATCTGGTCGTATCTCAAC	GCAGCCGAAACCAAGTAA	
<i>opt-2</i>	NCU04991	GCAAGCCATCCAGATGTT	GAATGTCGCGCCGATTAT	
NCU10381	NCU10381	GGCGGTGGGTATGTATAATG	CGATACTCAGGAAACCTTCAC	
NCU09874	NCU09874	CTAATTGCGCGTTCCAAATC	CTCACCAGACAAGGTAGTAGT	
<i>cat-1</i>	NCU08791	TACCACCAACCACCCTAA	GCCTGGTTGGCAGAAATA	
<i>cat-3</i>	NCU00355	CCGTCCTAGCCAGATTCTTA	CCCTTGATAACCTCGTCCT	
<i>cat-4</i>	NCU05169	TTAAGGAGACCGGAGAAGAC	CTTCTCAAGCTCATCCAATC	
<i>vma-1</i>	NCU01207	CCAACAAAATGGCGCCGAG	CCAATCATAATAGCAACACC	(2)

1. Chen, X.; Xue, W.; Zhou, J.; Zhang, Z.; Wei, S.; Liu, X.; Sun, X.; Wang, W.; Li, S. De-repression of CSP-1 activates adaptive responses to antifungal azoles. *Scientific Reports* **2016**, *6*, doi:10.1038/srep19447.2. Cusick, K.D.; Fitzgerald, L.A.; Pirlo, R.K.; Cockrell, A.L.; Petersen, E.R.; Biffinger, J.C. Selection and Evaluation of Reference Genes for Expression Studies with Quantitative PCR in the Model Fungus *Neurospora crassa* under Different Environmental Conditions in Continuous Culture. *Plos One* **2014**, *9*, doi:10.1371/journal.pone.0112706.

**Table S3.** Transcript levels of genes encoding oligopeptide (OPT) transporters and peptide transporters (PTR/POT).

Locus No.	Gene	Function	Homologue encoding gene in <i>C. albicans</i>	FPK M_W T	FPKM_ WT_Po xB	WT	30thK 1	30thK 2	26thV 1	24thV 2
NCU0873 8	<i>mfs-8</i>	MFS peptide transporter	PTR2, PTR22	1.000 0	0.41488 9	1.000 0	0.6528	0.5043	0.4861	0.2293
NCU0507 9	<i>mfs-9</i>	MFS peptide transporter	PTR2, PTR22	1.000 0	9.34739 4	1.000 0	0.2954	1.3339	1.7093	0.1345
NCU0317 1		Sexual differentiation process protein isp4	OPT1, OPT4, OPT5, OPT6	1.000 0	0.58546 4	0.995 7	0.6238	0.8258	0.8381	0.3725
NCU1076 3		small oligopeptide transporter	OPT1, OPT4, OPT5, OPT6	1.000 0	0.77155 7	1.000 0	0.6651	0.9748	1.0412	1.3482
NCU0635 2	<i>opt-4</i>	OPT-domain-containing protein	OPT1, OPT5	1.000 0	0.82513 5	1.097 6	1.0072	1.2861	1.3067	2.3329
NCU0839 7		unnamed protein product	OPT1, OPT4, OPT5, OPT6	1.000 0	0.26037 5	1.000 0	0.0822	0.2007	0.4778	0.0112
NCU0789 4	<i>opt-3</i>	oligopeptide transporter 2	OPT1, OPT4, OPT5, OPT6	1.000 0	64.1176 5	1.000 0	0.9208	0.6652	0.6222	1.9504
NCU1726 1		hypothetical protein	OPT2, OPT3, OPT4, OPT5, OPT6	1.000 0	1.45050 5	1.000 0	2.0439	1.4442	2.0969	1.4521
NCU1726 9	<i>opt-5</i>	oligopeptide transporter OPT	OPT5, OPT7	1.000 0	0.5 0	1.000 0	0.2397	1.4182	2.5003	1.2930
NCU0977 3	<i>opt-1</i>	oligopeptide transporter-1	OPT5	1.000 0	0.05332 8	1.000 0	0.0359	0.0847	0.2659	0.0023
NCU0499 1	<i>opt-2</i>	oligopeptide transporter-2	OPT5	1.000 0	0.28122 2	1.000 0	0.9219	0.5394	0.9100	1.4717
NCU1038 1		oligonucleotide transporter	OPT8	1.000 0	0.66411 9	1.000 0	1.1865	1.8073	1.5962	2.2886
NCU0987 4		hypothetical protein	OPT8	1.000 0	1.25637 5	1.000 0	0.9444	1.2600	0.8231	0.1457

**Table S4.** Summary of SNPs and Indel mutations in the tested strains.

Strain	Synonymous	Nonsynonymous	Insertion	Deletion
WT	256	135	24	40
30thC1	669	318	25	41
26thV1	675	318	25	41
30thK1	673	328	27	42
30thK2	659	318	20	36

Table S5. The information of SNPs.

Position	Ref	W	30th	26th	30th	30th	Ref_Base <->Sam- ple_Base	Co- don_Mu- tate	Aa_M utate	Gene_Id	Function	Mu- tated Strain	Kt c	Ter b	Am b	M bc	Pox b
15107 41	G	G	G	G	A	G	G<->A	GGC<->G AC	G<->D	NCU020 58	hp	30thK1	R <sup>a</sup>	R	N <sup>c</sup>	N	N
15107 76	A	A	A	A	G	A	A<->G	ACG<->G CG	T<->A	NCU020 58	hp	30thK1	R	R	N	N	N
34606 98	A	A	A	A	G	A	T<->C	CTA<->C CA	L<->P	NCU044 10	tRNA-pro- cessing-10	30thK1					
14888 46	T	T	T	T	G	G	T<->G	AAT<->C AT	N<->H	NCU020 65	DUF726 do- main-contain- ing protein	30thK1 , 30thK2	N	N	N	N	N
16139 65	A	A	A	G	G	A	A<->G	ATC<->G TC	I<->V	NCU020 34	RIP defective	26thV1 , 30thK1	N	N	N	N	N
16049 43	A	A	A	G	A	G	T<->C	CTC<->C CC	L<->P	NCU020 36	tRNA-splic- ing endonu- clease	26thV1 , 30thK2	N	N	S <sup>b</sup>	S	N
26930 80	A	A	A	G	A	G	T<->C	TCG<->C CG	S<->P	NCU025 48	hp	26thV1 , 30thK2	R	N	S	N	N
49928 9	G	G	G	T	G	T	G<->T	GTA<->T TA	V<->L	NCU034 91	RNA splicing factor Pad-1	26thV1 , 30thK2	R	N	N	N	N
30375 66	G	G	G	A	G	A	C<->T	ACG<->A TG	T<->M	NCU166 67	hp	26thV1 , 30thK2					
19214 95	T	T	T	A	T	A	T<->A	AGT<->A GA	S<->R	NCU036 41	Beta-gluco- sidase 2	26thV1 , 30thK2	N	N	N	N	N
13991 97	G	G	G	C	G	G	C<->G	CTT<->GT T	L<->V	NCU055 91	ABC trans- porter CDR4	26thV1	S	S	N	N	R


<sup>a</sup> R: The gene knockout mutant showed resistant phenotype (R) to the indicated antifungal drug compared to the WT strain. <sup>b</sup> S: The gene knockout mutant showed hypersensitive phenotype (S) to the indicated antifungal drug compared to the WT strain. <sup>c</sup> N: The gene knockout mutant showed no difference (N) to the indicated antifungal drug relative to the WT strain.

Table S6. The information of the Indels.


Ref_ID	Position	Type	Base	Strand	Gene_Id	Function	Mutated Strains	KT C	Ter b	Am b	MB C	Pox b
CM0022 36	1467874	D4	TACC	+	NCU163 36	3-hydroxyacyl-CoA dehydrogenase	30thK1					
CM0022 36	1489033	I3	GAT	-	NCU020 65	DUF726 domain-containing protein	30thK1, 26thV1	N	N	N	N	N
CM0022 36	1494042	I2	AC	+	NCU020 63	mitochondrial intermediate peptidase	30thK1, 30thK2					
CM0022 36	1504458	D1	G	-	NCU020 60	zinc metalloproteinase	30thK1	R <sup>a</sup>	R	N <sup>c</sup>	N	N
CM0022 36	1504461	D4	GCAC	-	NCU020 60	zinc metalloproteinase	30thK1	R	R	N	N	N
CM0022 36	1523039	D5	GATGA	+	NCU020 55	uridine nucleosidase Urh1	30thK1, 26thV1	R	N	N	N	N
CM0022 36	1538959	D1	T	-	NCU020 52	transcription initiation factor TFIIId 127kD subunit, variant	30thK1	N	R	N	N	N
CM0022 36	1543660	D1	T	+	NCU020 51	hp	30thK1, 30thK2, 26thV1	R	R	N	N	S <sup>b</sup>
CM0022 36	1574451	D5	TAGAA	-	NCU020 44	GTP-binding protein	30thK1					
CM0022 36	1580469	D4	GATT	-	NCU020 42	sterol-4alpha-carboxylate 3-dehydrogenase (decarboxylating)	30thK1	N	N	N	N	N
CM0022 36	1580475	I4	CAAC	-	NCU020 42	sterol-4alpha-carboxylate 4-dehydrogenase (decarboxylating)	30thK1	N	N	N	N	N
CM0022 36	1615222	D2	AA	-	NCU020 33	hp	30thK1, 26thV1	S	N	S	N	N
CM0022 36	1637568	D4	CAGG	+	NCU020 26	hp	30thK1	R	R	N	N	N
CM0022 36	1637669	D1	A	+	NCU020 26	hp	30thK1, 30thK2	R	R	N	N	N
CM0022 36	1641288	D9	AACAAC AAA	+	NCU020 24	hp	30thK1, 30thK2, 26thV1	N	N	N	N	N
CM0022 36	1641833	I4	AAAC	+	NCU020 24	hp	30thK1, 30thK2	N	N	N	N	N
CM0022 36	1641834	I1	A	+	NCU020 24	hp	30thK1	N	N	N	N	N
CM0022 36	1673214	D1	C	+	NCU020 14	hp	30thK1, 26thV1					
CM0022 36	1673216	D8	TTAAGG AG	+	NCU020 14	hp	30thK1, 26thV1					

Ref_ID	Position	Type	Base	Strand	Gene_Id	Function	Mutated Strains	KT	Ter	Am	MB	Pox
								C	b	b	C	b
CM0022 36	1675626	I2	TT	-	NCU02012	hp	30thK1, 30thK2	R	N	S	S	S
CM0022 36	1704179	I4	GATG	-	NCU02005	phosphoadenosine phosphosulfate reductase	30thK1, 26thV1					
CM0022 36	1736108	I5	GGCCG	-	NCU14007	hp	30thK1, 26thV1					
CM0022 36	1749270	D1	A	-	NCU01993	ethanolaminephosphotransferase	30thK1, 30thK2	R	N	N	N	N
CM0022 36	1818708	I2	TT	+	NCU01973	SET-8	30thK1	N	N	N	N	N
CM0022 36	1904395	I2	GC	+	NCU01947	hp	30thK1	N	R	N	N	N
CM0022 37	2943417	D1	T	+	NCU01620	hp	30thK1	N	N	N	N	N
CM0022 36	5046154	I1	T	+	NCU03246	tyrosine-protein phosphatase CDC14	30thK1	R	N	N	N	S
CM0022 36	6108158	I1	T	+	NCU07390	hp	30thK1					
CM0022 36	117982	D4	CTTC	+	NCU08055	glycoside hydrolase family 3 protein ZIP-1	30thK2	N	N	N	N	N
CM0022 36	1730716	I2	AA	-	NCU01997	ABC transporter	30thK2	N	R	N	N	N
CM0022 36	1671820	I3	TCC	+	NCU02014	hp	30thK2, 26thV1					
CM0022 42	3212857	I1	T	-	NCU02243	hp	30thK2, 26thV1	N	N	N	N	N
CM0022 36	4307175	I1	G	-	NCU09308	glycoprotease	30thK2	N	R	N	N	N
CM0022 40	5238569	I1	A	-	NCU04216	hp	30thK2, 26thV1					
CM0022 36	1835539	D1	T	+	NCU01967	hp	26thV1	R	N	S	N	R
CM0022 36	8866762	I1	G	-	NCU02867	hp	26thV1	R	R	R	N	N
KC6837 08	14197	D1	C	+	NCU16302	mitochondrial ribosomal protein S5 (mitochondrion)	26thV1					


<sup>a</sup> R: The gene knockout mutant showed resistant phenotype (R) to the indicated antifungal drug compared to the WT strain. <sup>b</sup> S: The gene knockout mutant showed hypersensitive phenotype (S) to the indicated antifungal drug compared to the WT strain. <sup>c</sup> N: The gene knockout mutant showed no difference (N) to the indicated antifungal drug relative to the WT strain.



**Figure S1.** *N. crassa* acquired multidrug resistance under azole stress. (A) Drug susceptibility test of the indicated strains to different antifungals at designated concentrations. Two microliter aliquots of conidial suspension ( $2 \times 10^6$  conidia/mL) were inoculated in the center of plates ( $\phi 90$ -mm) with or without the antifungals. The plates were then incubated at 28°C for the indicated time. The experiment was independently repeated at least three times. (B) Relative growth inhibition rates were calculated based on colony diameters at indicated hours after drug treatment. Values from three replicates were used for statistical analysis. Means of the inhibition rates are shown, and standard deviations are marked with error bars. Difference significance between the evolved strains and the ancestral WT strain were estimated by the t-test and marked as \* ( $p < 0.05$ ), \*\* ( $p < 0.01$ ), and \*\*\* ( $p < 0.001$ ). (C) Relative growth inhibition rates were calculated based on colony diameters of colonies at indicated growth time. Values from three replicates were used for statistical analysis. Means of the inhibition rates are shown, and standard deviations are marked with error bars. Significance between the evolved strains and the ancestral WT strain was estimated by the t-test. Values with  $p < 0.001$ ,  $0.001 < p < 0.01$ , and  $0.01 < p < 0.05$  are marked with \*\*\*, \*\* and \*, respectively. (D) The spore morphology of the evolved populations and the ancestral WT strain. The abbreviation the antifungal drugs are explained: ITC (itraconazole), FLC (fluconazole), TDF (triadimefon), AMO (amorolfine), and CAS (caspofungin).




**Figure S2.** Drug susceptibility test of gene knockout mutants for transmembrane transporters, including (A) *cdr4*<sup>KO</sup>, *abc-8*<sup>KO</sup>, *abc-3*<sup>KO</sup> to KTC, VRC and Terb, (B) *cdr4*<sup>KO</sup> to MBC, and (C) *atrif-2*<sup>KO</sup>, *mfs-9*<sup>KO</sup>, and *NCU03171*<sup>KO</sup> to PoxB. Two microliter aliquots of conidial suspension ( $2 \times 10^6$  conidia/mL) were inoculated in the center of plates ( $\phi 90$ -mm) with or without the antifungals. The plates were then incubated at 28°C for the indicated time. The experiment was independently repeated at least three times.




**Figure S3.** Effects of *cdr4* deletion or overexpression on drug susceptibility. Two microliter aliquots of conidial suspension ( $2 \times 10^6$  conidia/mL) were inoculated in the center of plates ( $\phi 90$ -mm) with or without the antifungals. The plates were then incubated at 28°C for the indicated time. The experiment was independently repeated at least three times.





**Figure S4.** Drug susceptibility test of knockout mutants of genes with SNPs or Indels in the evolved resistant strains. Two microliter aliquots of conidial suspension ( $2 \times 10^6$  conidia/mL) were inoculated in the center of plates ( $\phi 90$ -mm) with or without the antifungals. The plates were then incubated at 28°C for the indicated time. The experiment was independently repeated at least twice.



**Figure S5.** Transcript levels of catalase encoding genes (*cat-1*, *cat-3* and *cat-4*) in the evolved resistant strains and WT. Transcript levels were measured by qRT-PCR, calculated by  $2^{-\Delta\Delta C_t}$  method and normalized to  $\beta$ -tubulin. The results presented here are means of two biological replicates.